Instanosis
Private Company
Funding information not available
Overview
Instanosis is an early-stage, private diagnostics company focused on revolutionizing point-of-care testing through its proprietary InstaStrip technology, which offers dramatically higher sensitivity than traditional lateral flow assays. The company's initial commercial focus is on the opioid crisis, with FDA-cleared, CLIA-waived rapid tests for fentanyl, xylazine, and nitazene in urine and powders, targeting hospitals, harm reduction programs, and law enforcement. Backed by NIH funding and peer-reviewed clinical validation, Instanosis is positioned to address critical gaps in rapid, accurate drug screening and has a pipeline leveraging its platform for other diagnostic applications.
Technology Platform
Proprietary 'InstaStrip' lateral flow assay technology enabling ultra-sensitive (low ng/mL), instrument-free detection with high contrast visual readouts. Underlying platform may include digital signal amplification methods (e.g., microbubbling digital assay) for femtomolar sensitivity.
Opportunities
Risk Factors
Competitive Landscape
Instanosis competes in the rapid toxicology testing market against large, diversified diagnostics companies (e.g., Abbott, Siemens Healthineers) and specialized toxicology firms. Its key differentiator is extreme sensitivity (25x more sensitive by its claims) and multiplexing for novel adulterants like xylazine, areas where traditional tests are less effective. It also competes with simpler, less sensitive fentanyl test strips commonly used in harm reduction settings.